Tao Xie to Humans
This is a "connection" page, showing publications Tao Xie has written about Humans.
Connection Strength
0.503
-
Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease". Mov Disord. 2024 Apr; 39(4):760-761.
Score: 0.031
-
Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome. Mov Disord. 2023 02; 38(2):304-312.
Score: 0.028
-
Disparities in diagnosis, treatment and survival between Black and White Parkinson patients. Parkinsonism Relat Disord. 2021 06; 87:7-12.
Score: 0.025
-
Disease course and treatment patterns in progressive supranuclear palsy: A real-world study. J Neurol Sci. 2021 Feb 15; 421:117293.
Score: 0.024
-
Interference of subcutaneous implantable cardioverter defibrillator by deep brain stimulation. Parkinsonism Relat Disord. 2020 12; 81:75-77.
Score: 0.024
-
Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018 09; 89(9):989-994.
Score: 0.020
-
Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease. Mov Disord. 2017 01; 32(1):176.
Score: 0.018
-
Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
Score: 0.018
-
Author Response. Neurology. 2015 Aug 11; 85(6):557.
Score: 0.017
-
Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS. Neurology. 2015 Aug 04; 85(5):479-80.
Score: 0.017
-
Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology. 2015 Jan 27; 84(4):415-20.
Score: 0.016
-
DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology. 2014 Feb 18; 82(7):636-7.
Score: 0.015
-
Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012 Oct 16; 79(16):1744; author reply 1744.
Score: 0.014
-
Diagnostic biomarkers of Parkinson's disease: what gain at what cost? J Neurol Neurosurg Psychiatry. 2012 Aug; 83(8):769.
Score: 0.014
-
Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012 Oct; 83(10):1015-7.
Score: 0.014
-
Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. Mov Disord. 2012 May; 27(6):799-800.
Score: 0.013
-
Using global team science to identify genetic parkinson's disease worldwide. Ann Neurol. 2019 08; 86(2):153-157.
Score: 0.011
-
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 03; 60:138-145.
Score: 0.010
-
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
Score: 0.010
-
Dystonia treatment: Patterns of medication use in an international cohort. Neurology. 2017 Feb 07; 88(6):543-550.
Score: 0.009
-
Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025.
Score: 0.009
-
Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B). Ann Neurol. 2024 Dec; 96(6):1092-1103.
Score: 0.008
-
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
Score: 0.008
-
Common Variants Near ZIC1 and ZIC4 in Autopsy-Confirmed Multiple System Atrophy. Mov Disord. 2022 10; 37(10):2110-2121.
Score: 0.007
-
Recommendations for Virtual Administration of the PSP Rating Scale. Mov Disord. 2022 09; 37(9):1960-1961.
Score: 0.007
-
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Mov Disord. 2022 06; 37(6):1265-1271.
Score: 0.007
-
Pan-cancer analyses reveal genomics and clinical characteristics of the melatonergic regulators in cancer. J Pineal Res. 2021 Oct; 71(3):e12758.
Score: 0.006
-
Melatonin reverses nasopharyngeal carcinoma cisplatin chemoresistance by inhibiting the Wnt/ß-catenin signaling pathway. Aging (Albany NY). 2020 03 23; 12(6):5423-5438.
Score: 0.006
-
N-Oxide polymer-cupric ion nanogels potentiate disulfiram for cancer therapy. Biomater Sci. 2020 Mar 17; 8(6):1726-1733.
Score: 0.006
-
Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy. Biomaterials. 2020 05; 240:119902.
Score: 0.006
-
Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling. Cell Rep. 2020 02 11; 30(6):1935-1950.e8.
Score: 0.006
-
Consensus Paper: Experimental Neurostimulation of the Cerebellum. Cerebellum. 2019 Dec; 18(6):1064-1097.
Score: 0.006
-
Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
Score: 0.006
-
Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
Score: 0.006
-
Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp. 2019 12 01; 40(17):5094-5107.
Score: 0.006
-
Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol. 1999 Jul; 56(1):31-8.
Score: 0.006
-
Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord. 2019 08; 65:178-183.
Score: 0.005
-
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558.
Score: 0.005
-
Catechol-O-methyltransferase inhibitors in Parkinson's disease. Lancet. 1998 Jun 27; 351(9120):1966.
Score: 0.005
-
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018 02; 33(2):282-288.
Score: 0.005
-
High resolution single strand conformation polymorphism analysis using formamide and ethidium bromide staining. Mol Pathol. 1997 Oct; 50(5):276-8.
Score: 0.005
-
G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord. 1997 May; 12(3):426-7.
Score: 0.005
-
Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord. 2016 12; 31(12):1874-1882.
Score: 0.005
-
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord. 2016 06; 31(6):924-32.
Score: 0.004
-
Pathological findings of anti-Yo cerebellar degeneration with Holmes tremor. J Neurol Neurosurg Psychiatry. 2015 Jan; 86(1):121-2.
Score: 0.004
-
Anticholinergic responsive cyclic myoclonus. Mov Disord. 2013 Mar; 28(3):401-2.
Score: 0.004
-
Distribution of catechol-O-methyltransferase expression in human central nervous system. Neuroreport. 1998 Aug 24; 9(12):2861-4.
Score: 0.003
-
Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology. 2003 Dec; 45(7):1011-8.
Score: 0.002
-
Further studies in xenobiotic metabolism and Parkinson's disease. Adv Neurol. 2001; 86:105-13.
Score: 0.002